Crinetics Pharmaceuticals (CRNX) Non-Current Assets (2017 - 2025)
Crinetics Pharmaceuticals has reported Non-Current Assets over the past 9 years, most recently at $77.9 million for Q4 2025.
- For Q4 2025, Non-Current Assets rose 31.6% year-over-year to $77.9 million; the TTM value through Dec 2025 reached $295.3 million, up 22.68%, while the annual FY2025 figure was $77.9 million, 31.6% up from the prior year.
- Non-Current Assets for Q4 2025 was $77.9 million at Crinetics Pharmaceuticals, up from $74.8 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $77.9 million in Q4 2025 and troughed at $5.0 million in Q1 2022.
- A 5-year average of $36.3 million and a median of $33.9 million in 2023 define the central range for Non-Current Assets.
- Biggest five-year swings in Non-Current Assets: fell 14.44% in 2021 and later soared 903.16% in 2023.
- Year by year, Non-Current Assets stood at $6.3 million in 2021, then rose by 11.07% to $7.0 million in 2022, then skyrocketed by 775.29% to $61.2 million in 2023, then decreased by 3.26% to $59.2 million in 2024, then surged by 31.6% to $77.9 million in 2025.
- Business Quant data shows Non-Current Assets for CRNX at $77.9 million in Q4 2025, $74.8 million in Q3 2025, and $72.3 million in Q2 2025.